Dyadic International
Dyadic International (Dyadic Applied BioSolutions) is a publicly traded industrial biotechnology company that uses its proprietary C1 and Dapibus™ filamentous fungal platforms to produce and license recombinant proteins for life sciences, food & nutrition, and bio-industrial customers globally.
- Company typePublic
- Founded1979
- HeadquartersJupiter, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dyadic International does
Dyadic International, operating commercially as Dyadic Applied BioSolutions, is a global industrial biotechnology company that develops and commercializes recombinant proteins using two proprietary microbial expression platforms: C1 and Dapibus™, both based on the filamentous fungal host Thermothelomyces heterothallica discovered in the 1990s. The company serves three end markets — Life Sciences (recombinant human proteins for research, diagnostics, and bioprocessing), Food & Nutrition (animal-free proteins such as lactoferrin, bovine alpha-lactalbumin, and dairy enzymes for infant formula and functional foods), and Bio-Industrial (cellulase, beta-glucanase, xylanase, and pulp & paper enzyme cocktails). The platforms have been validated at >100,000L fermentation scale, hold GRAS designation for food-grade applications, support cGMP manufacturing, and have completed a first-in-human Phase I study. Per the company, the C1 platform can progress from a codon-optimized gene sequence to purified antigen or monoclonal antibody in approximately 15 days — a key speed claim vs. mammalian-cell alternatives.
Revenue is generated through four streams: direct product sales of recombinant proteins (e.g., AlbuFree™ DX human albumin with Proliant Health & Biologicals, DNase I with Fermbox Bio); license and milestone payments from partners manufacturing in-house (IBT Bioservices, Fermbox, Proliant); custom R&D services (strain engineering and process development); and grant funding from global health organizations (Gates Foundation, CEPI). Distribution combines direct enterprise sales, technology licensing, partner-led commercialization, and co-development arrangements. The company operates globally with headquarters in Jupiter, Florida and active partnerships spanning North America, Europe, India, Japan, and South Korea. Founded in 1979 by Mark A. Emalfarb (current CEO), the company is publicly traded on NASDAQ (DYAI) and rebranded in 2025 to reflect its pivot from a development-stage platform to a product-driven commercial entity. FY 2025 revenue was approximately $3.09M with a $7.36M net loss, and the company received a Nasdaq minimum bid price deficiency notice in December 2025.
Dyadic International firmographics
Firmographics- Name
- Dyadic International
- Legal name
- Dyadic International, Inc.
- Website
- https://dyadic.com
- Company type
- Public
- Founded year
- 1979
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Dyadic International (Dyadic Applied BioSolutions) is a publicly traded industrial biotechnology company that uses its proprietary C1 and Dapibus™ filamentous fungal platforms to produce and license recombinant proteins for life sciences, food & nutrition, and bio-industrial customers globally.
- Ownership category
- akta.pro rank
Dyadic International industry classification
Industry- Product category
- Industrial Biotechnology / Recombinant Protein Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Food Manufacturing (311)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Food And Kindred Products (2000)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL), Microbial Coagulants & Fermentation-Derived Enzymes (Chymosin, Microbial Rennet Systems) (AFAJAJAJ), Mycoprotein & Fungal Proteins (Fusarium/Mycelium-Based) (AFAJAHAE)
Keywords
Where Dyadic International is headquartered
LocationHeadquarters
- HQ city
- Jupiter
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Dyadic International business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Product Sales: Recurring revenue from product sales of recombinant proteins including research-grade proteins, GMP-grade materials, and commercial proteins for diagnostics, cell culture, and bioprocessing applications. Revenue increased 182% year-over-year to $1.11M in Q1 2026 driven by increases in R&D revenue and product launches.
- License and Milestone Revenue: License fees and milestone payments from partners licensing C1 or Dapibus™ platforms for in-house manufacturing. Partners include Proliant Health & Biologicals, IBT Bioservices, and Fermbox Bio arrangements.
- Research and Development Services: Custom strain engineering, technology transfer, and process development services. Revenue categorized as 'research and development revenue' in financial statements at $403,590 in Q1 2026.
- Grant Revenue: Grant funding from global health organizations including CEPI and Gates Foundation for pandemic preparedness and infectious disease research. Grant revenue was $487,366 in Q1 2026.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Dyadic International product offering
Product offeringCore offering
Dyadic International (doing business as Dyadic Applied BioSolutions) develops and manufactures recombinant proteins and enzymes using its proprietary C1 and Dapibus™ filamentous fungal microbial expression platforms. The company sells commercial-grade proteins for life sciences (e.g., AlbuFree™ DX recombinant human albumin, DNase I, transferrin, FGF, alpha-lactalbumin), animal-free food proteins (lactoferrin, bovine alpha-lactalbumin, dairy enzymes), and industrial enzyme cocktails (cellulase, xylanase, pulp & paper enzymes). Revenue is generated through direct product sales, technology licensing, custom strain development services, and grant-funded research collaborations with global health organizations.
Product overview
Dyadic Applied BioSolutions operates as a platform company with two proprietary microbial expression systems—C1 and Dapibus™—that serve as the foundation for a growing portfolio of commercial recombinant proteins and enzymes. The C1 platform is production-proven at commercial scale with Phase I clinical validation, while the Dapibus platform is optimized for yield and cost in food, nutrition, and industrial applications. The company's product portfolio spans three market segments: Life Sciences (recombinant human proteins including AlbuFree DX albumin, DNase I, transferrin, FGF, and alpha-lactalbumin for research, diagnostics, and bioprocessing); Food & Nutrition (animal-free proteins including lactoferrin, bovine alpha-lactalbumin, bovine FGF, bovine transferrin, and dairy enzymes for functional foods, infant formula, and cultured meat); and Bio-Industrial (enzyme cocktails including cellulase complexes, beta-glucanase, xylanase, and pulp & paper enzymes for biofuels, textiles, and specialty chemicals). The platforms enable flexible, scalable, animal-free protein production from lab to commercial scale (>100,000 liters).
Differentiator
Problem solved
Functional benefit
Brands
- AlbuFree DX: Recombinant human albumin product commercialized with Proliant Health & Biologicals for research, diagnostic, and cell culture applications
- C1 Platform
- Dapibus Platform
Products and services
- AlbuFree™ DX Recombinant Human Albumin Recombinant human albumin produced via the C1 microbial platform for research, diagnostic, and cell culture applications, offering an animal-free, scalable alternative to plasma-derived albumin. Commercialized with Proliant Health & Biologicals.
- Animal-Origin-Free Recombinant DNase I (RNase-Free) Animal-origin-free recombinant DNase I enzyme for RNA workflows in diagnostics and gene therapy manufacturing, enabling removal of genomic DNA from RNA samples. Co-developed and commercialized with Fermbox Bio.
- Recombinant Human Transferrin Recombinant human transferrin for research, diagnostic, and cell culture media applications, providing iron transport functionality without animal-derived components.
- Recombinant Human FGF (Fibroblast Growth Factor) Recombinant human fibroblast growth factor for research, diagnostic, and cell culture media applications supporting cell growth and metabolism.
- Recombinant Human Alpha-Lactalbumin Recombinant human alpha-lactalbumin for research, diagnostic, and cell culture media applications, designed as nutritional whey protein for infant formula, medical, and wellness applications.
- Recombinant Human Lactoferrin Recombinant human lactoferrin for premium and functional nutrition applications, providing immune-supportive protein properties produced via microbial fermentation.
- Recombinant Bovine Alpha-Lactalbumin Recombinant bovine alpha-lactalbumin for infant formula, functional foods, and wellness applications, enabling animal-free dairy protein production. Developed under partnership with BRIG Bio.
- Recombinant Bovine FGF Recombinant bovine fibroblast growth factor for food, nutrition, and cultured meat applications, supporting cell growth and metabolism in bioprocessing.
- Recombinant Bovine Transferrin Recombinant bovine transferrin for food, nutrition, and cultured meat applications, providing iron-binding protein functionality for cell culture and nutrition.
- Non-Animal Dairy Enzymes High-performance enzymes for cheese and dairy processing workflows produced via microbial fermentation, replacing animal-derived enzyme sources.
- Pulp & Paper Enzyme Cocktail Industrial-grade glycolytic enzyme blend for pulp & paper and biomass conversion applications, enabling efficient enzymatic processing of lignocellulosic materials.
- Cellulase Enzyme Complexes Enzyme blends supporting cellulose degradation and fiber modification in industrial applications including biofuels and textile processing.
- Beta-Glucanase and Xylanase Enzymes Enzymes improving viscosity reduction, yield, and clarity in brewing and food processing applications through targeted polysaccharide hydrolysis.
- Cellulosic Enzyme Cocktail (Fermbox Partnership) Custom enzyme formulation developed with Fermbox partnership for biomass degradation and cellulosic ethanol production, enabling sustainable biofuel manufacturing.
- C1 Protein Production Platform Production-proven filamentous fungal expression platform using Thermothelomyces heterothallica, validated at commercial scale exceeding 100,000 liters, with Phase I clinical validation and cGMP capability. Used for complex protein production with high yield and low cost; can progress from gene sequence to purified antigen or monoclonal antibody in approximately 15 days. Licensed to partners and used for in-house manufacturing of recombinant proteins.
- Dapibus™ Expression System Yield and cost-optimized microbial expression platform for high-volume protein production in food, nutrition, and industrial applications, featuring sustainable, low-cost manufacturing via low-carbon precision fermentation and animal-free production. Licensed to partners such as Fermbox Bio and Inzymes.
- C1 HCP ELISA Test ELISA-based quality assurance test for detecting host cell proteins (HCP) in biomanufacturing processes using Dyadic's C1 platform, co-developed with Cygnus Technologies.
Quantifiable outcome
- C1 platform progresses from gene sequence to purified antigen or monoclonal antibody in approximately 15 days
- +3 more outcomes
Companies that use Dyadic International
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles4 records
Dyadic International technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Dyadic International partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major and minor.
- CEPI (Coalition for Epidemic Preparedness Innovations)coreResearch proposals submitted to CEPI's Ebola funding call as part of Dyadic's pandemic preparedness activities. CEPI funding would support development of rapid response manufacturing capabilities for Ebola and other infectious diseases using the C1 platform.
- Fondazione Biotecnopolo di Siena and European Vaccines HubcoreMonoclonal antibody initiative targeting Ebola and other infectious disease threats. Collaboration with European Vaccines Hub for rapid development and manufacturing of antibody therapeutics using Dyadic's C1 platform.
- Scripps ResearchcoreCollaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus which causes Hantavirus Pulmonary Syndrome. Partnership leverages Dyadic's proprietary C1 microbial protein production platform combined with Scripps Research's structure-based protein design expertise for rapid, scalable biologic manufacturing for pandemic preparedness. Builds on prior Andes virus antibody work and prior collaborations on Marburg and Ebola viruses.
- IBT BioservicesmajorOEM distribution agreement for Dyadic's recombinant proteins and biologic manufacturing inputs. IBT Bioservices distributes Dyadic products as part of their biopharmaceutical service offerings.
- Fermbox BiocoreExpanded collaboration including commercial launch of animal-origin-free recombinant DNase I (RNase-Free) for RNA workflows in diagnostics and gene therapy. Partnership for custom enzyme formulations including cellulosic enzyme cocktail for biomass degradation and cellulosic ethanol production.
- InterlinkminorAsia-Pacific partnership for market expansion into Japan and South Korea. Enables broader geographic reach for Dyadic's products and platform technology in key Asian markets.
- Proliant Health & BiologicalscoreCommercial launch of AlbuFree™ DX recombinant human albumin using Dyadic's production platform. Dyadic eligible to receive a share of profits from product sales. Product for research, diagnostic, and cell culture applications.
- BRIG BiomajorDevelopment agreement for recombinant bovine alpha-lactalbumin for infant formula, functional foods, and wellness applications. Dyadic to build proprietary strain for partner IP.
- VTT Technical Research Centre of FinlandminorResearch and development partnership for enzyme and protein development applications. VTT logo appears on Dyadic's partners page indicating active collaboration.
- InzymesminorStrategic partnership for enzyme products and bio-industrial applications. Inzymes logo appears on Dyadic's partners page indicating active collaboration.
- RubicminorPartnership for protein development and commercialization. Rubic logo appears on Dyadic's partners page indicating active collaboration.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Dyadic International competitors and assessment
Company assessmentDirect peers
- Perfect Day: Precision fermentation company producing animal-free whey proteins for food applications. Directly comparable to Dyadic's Dapibus platform and food/nutrition segment targeting recombinant alpha-lactalbumin, lactoferrin, and other dairy proteins via microbial fermentation.
- Codexis: Engineered enzymes and biocatalysts company using proprietary protein engineering platforms for pharmaceutical and industrial applications. Closely comparable to Dyadic's protein engineering and platform-licensing model, including a similar mixture of licensing revenue and direct product sales.
- AB Enzymes: Specialty industrial enzyme manufacturer serving food, beverage, and industrial processing markets. Closely comparable to Dyadic's bio-industrial enzyme portfolio (cellulases, xylanases, beta-glucanases) and its food/nutrition dairy enzymes.
Broad incumbents
- Novonesis (formerly Novozymes): Global leader in industrial enzymes and microbial protein production with deep fermentation expertise. Directly comparable to Dyadic's bio-industrial enzyme segment and to the broader Dapibus platform thesis, though Novonesis operates at vastly greater scale and across many more end markets.
- International Flavors & Fragrances (IFF): Diversified ingredients company with a major Health & Biosciences division producing enzymes, cultures, and fermentation-derived proteins. Comparable to Dyadic's bio-industrial enzyme offering and a potential large customer for the Dapibus platform in food and industrial markets.
- Sartorius AG: Bioprocessing solutions provider serving biopharmaceutical manufacturers with cell lines, fermentation technologies, and process equipment. Comparable to the broader C1 platform ecosystem where Dyadic competes for biopharma manufacturing partnerships.
- GenScript Biotech: Life sciences tools and biopharmaceutical services company with proprietary recombinant protein production and biologics manufacturing capabilities. Comparable as a competitor/supplier in the life sciences segment where Dyadic sells research-grade proteins and biologics inputs.
- Ginkgo Bioworks: Synthetic biology platform company engineering microbial strains for industrial applications across food, industrial enzymes, and biopharma. Closely comparable to Dyadic's C1 and Dapibus platform thesis of using proprietary microbial hosts for protein production at scale.
- DSM-Firmenich: Global nutrition, health, and bioscience company with significant precision fermentation and enzyme capabilities. Comparable as a large incumbent partner/customer profile for Dyadic's food, nutrition, and industrial enzyme segments.
Emerging players
- The EVERY Company (formerly Clara Foods): Precision fermentation company producing animal-free proteins such as ovalbumin and dairy proteins using microbial expression. Directly comparable to Dyadic's food and nutrition segment and alternative-protein commercialization model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Dyadic International social profiles
Digital presenceDyadic International compliance and trust
Trust signalCompliance2 records
Dyadic International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dyadic International leadership team
Management profileNumber of profiles
Profiles2 records
Dyadic International funding detail
Funding detailFunding overview
Funding rounds10 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dyadic International M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dyadic International
What does Dyadic International do?
Dyadic International (doing business as Dyadic Applied BioSolutions) develops and manufactures recombinant proteins and enzymes using its proprietary C1 and Dapibus™ filamentous fungal microbial expression platforms. The company sells commercial-grade proteins for life sciences (e.g., AlbuFree™ DX recombinant human albumin, DNase I, transferrin, FGF, alpha-lactalbumin), animal-free food proteins (lactoferrin, bovine alpha-lactalbumin, dairy enzymes), and industrial enzyme cocktails (cellulase, xylanase, pulp & paper enzymes). Revenue is generated through direct product sales, technology licensing, custom strain development services, and grant-funded research collaborations with global health organizations.
Is Dyadic International a public or private company?
Dyadic International is a public company. It is classified as public and is currently operating.
When was Dyadic International founded?
Dyadic International was founded in 1979. It employs 51 to 100 people.
Where is Dyadic International based?
Dyadic International is headquartered in Jupiter, United States, in the North America region.
How does Dyadic International make money?
Four revenue lines are on record. Product Sales are the primary driver. The others are license and Milestone Revenue, research and Development Services and grant Revenue.
Who are Dyadic International's main competitors?
Direct peers on record are Perfect Day, Codexis and AB Enzymes. Broad incumbents are Novonesis (formerly Novozymes), International Flavors & Fragrances (IFF), Sartorius AG, GenScript Biotech, Ginkgo Bioworks and DSM-Firmenich. The EVERY Company (formerly Clara Foods) is listed as an emerging player.
Does Dyadic International have an API?
No public API is recorded for Dyadic International.
What industry is Dyadic International in?
Dyadic International's product category is Industrial Biotechnology / Recombinant Protein Manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins). Its NAICS code is 325414 and its SIC code is 2836.